Additionally, in models of MYC-driven breast cancer, the combined use of metformin with venetoclax or navitoclax suppressed tumor cell growth effectively and induced immune infiltration into tumors, which adds new insight into the strategy of cotargeting AMPK and BCL-2 to enhance synergy [132]. The gene discussed is BCL2; the disease is neoplasm.